High Anti-Mullerian Hormone Strongly Correlates With Reproductive Outcomes in Women Undergoing Assisted Reproduction Publisher Pubmed



Jabarpour M¹ ; Amidi F¹ ; Rostami S¹ ; Aleyasin A^{2, 3} ; Aghahosseini M^{2, 3} ; Khodarahmian M⁴ ; Najafian A^{2, 3} ; Hosseinimousa S^{2, 3} ; Abbasi Y⁵ ; Nashtaei MS^{1, 2}
Source: Clinical Laboratory Published:2023

Abstract

Background: In a retrospective cohort of 881 women with gynecologic and unexplained infertility, we aimed to study the relationship between serum AMH levels and ART outcomes. This retrospective cohort includes 881 infertile women aged 20 - 45 who underwent their first fresh autologous non–preimplantation genetic diagnosis ART cycles between 2012 and 2020. Methods: We assessed the correlation between AMH levels and reproductive outcomes among infertile women with different causes of infertility (including endometriosis, polycystic ovary syndrome (PCOS), and unexplained infertility). Results: We found a strong correlation between high AMH levels and reproductive outcomes independent of age and the cause of infertility in women undergoing ART. In all patients with gynecologic and unexplained infertility, higher AMH correlated with the improved number of oocytes (p < 0.001), MII oocytes (p < 0.001), good-quality embryos (p < 0.001), chemical pregnancy rate (p < 0.001 in women < 37; and p = 0.002 in women over 37), clinical pregnancy rate (p < 0.05), and live birth rate (p = 0.05). Conclusions: Serum AMH concentrations can be invaluable for predicting ovarian reserve and reproductive outcomes in young and advanced-age infertile patients undergoing ART. However, it should not be used as the sole predictive marker for disqualifying infertile women from ART treatment. Further large cohort studies are warranted to determine an exact cutoff point for AMH to provide an accurate ART success prediction. (Clin. Lab. 2023;69:2479-2488. DOI: 10.7754/Clin.Lab.2023.230524) © 2023 Verlag Klinisches Labor GmbH. All rights reserved.